Literature DB >> 18317690

Knockdown of GluR1 expression by RNA interference inhibits glioma proliferation.

John F de Groot1, Yuji Piao, Li Lu, Gregory N Fuller, W K Alfred Yung.   

Abstract

High-grade gliomas release excitotoxic concentrations of glutamate which contributes to their malignant phenotype. To improve our understanding of the mechanisms by which glutamate enhances tumor growth and invasion, we examined alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA)-mediated signaling in glioma cell lines. shRNA was used to stably knockdown GluR1, the most abundant AMPA receptor subunit in glioma, to evaluate its role in tumor signaling, proliferation and tumorigenicity. In a tissue array, there was a statistically significant increase in GluR1 expression in glioblastoma samples compared to anaplastic astrocytoma and low-grade tumors. In vitro, we observed a time and dose-dependent increase in MAPK phosphorylation following exposure to AMPA, which was blocked with AMPA receptor antagonists and the MEK1 inhibitor PD98059. Retroviral delivery of GluR1 shRNA in U251 and U87 glioma cells reduced GluR1 protein expression, inhibited AMPA-mediated increases in MAPK phosphorylation, and decreased glioma proliferation in vitro. U251 and U87 shGluR1 cells implanted into the flanks of nude mice grew slower than controls, which correlated with a decrease in proliferation measured by Ki-67 staining and an increase in apoptosis. These results suggest that AMPA receptors are abundantly expressed in high-grade gliomas and gene silencing of the GluR1 AMPA receptor subunit results in abrogation of AMPA-mediated signaling and tumor growth.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18317690     DOI: 10.1007/s11060-008-9552-2

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  42 in total

1.  GRASP-1: a neuronal RasGEF associated with the AMPA receptor/GRIP complex.

Authors:  B Ye; D Liao; X Zhang; P Zhang; H Dong; R L Huganir
Journal:  Neuron       Date:  2000-06       Impact factor: 17.173

2.  Inducible shRNA expression for application in a prostate cancer mouse model.

Authors:  Frank Czauderna; Ansgar Santel; Michael Hinz; Melanie Fechtner; Birgit Durieux; Gerald Fisch; Frauke Leenders; Wolfgang Arnold; Klaus Giese; Anke Klippel; Jörg Kaufmann
Journal:  Nucleic Acids Res       Date:  2003-11-01       Impact factor: 16.971

Review 3.  The glutamate receptor ion channels.

Authors:  R Dingledine; K Borges; D Bowie; S F Traynelis
Journal:  Pharmacol Rev       Date:  1999-03       Impact factor: 25.468

4.  Compromised glutamate transport in human glioma cells: reduction-mislocalization of sodium-dependent glutamate transporters and enhanced activity of cystine-glutamate exchange.

Authors:  Z C Ye; J D Rothstein; H Sontheimer
Journal:  J Neurosci       Date:  1999-12-15       Impact factor: 6.167

Review 5.  Regulators and effectors of ras proteins.

Authors:  G Bollag; F McCormick
Journal:  Annu Rev Cell Biol       Date:  1991

Review 6.  Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 1: Growth factor and Ras signaling pathways.

Authors:  Herbert B Newton
Journal:  Expert Rev Anticancer Ther       Date:  2003-10       Impact factor: 4.512

7.  Benzothiadiazides inhibit rapid glutamate receptor desensitization and enhance glutamatergic synaptic currents.

Authors:  K A Yamada; C M Tang
Journal:  J Neurosci       Date:  1993-09       Impact factor: 6.167

Review 8.  Role of MAP kinase in tumor progression and invasion.

Authors:  Kaladhar B Reddy; Sanaa M Nabha; Natasha Atanaskova
Journal:  Cancer Metastasis Rev       Date:  2003-12       Impact factor: 9.264

9.  Mitogen-activated protein kinase/extracellular signal-regulated protein kinase activation by oncogenes, serum, and 12-O-tetradecanoylphorbol-13-acetate requires Raf and is necessary for transformation.

Authors:  J Troppmair; J T Bruder; H Munoz; P A Lloyd; J Kyriakis; P Banerjee; J Avruch; U R Rapp
Journal:  J Biol Chem       Date:  1994-03-04       Impact factor: 5.157

10.  Membrane depolarization and calcium influx stimulate MEK and MAP kinase via activation of Ras.

Authors:  L B Rosen; D D Ginty; M J Weber; M E Greenberg
Journal:  Neuron       Date:  1994-06       Impact factor: 17.173

View more
  35 in total

Review 1.  Glutamate and the biology of gliomas.

Authors:  John de Groot; Harald Sontheimer
Journal:  Glia       Date:  2010-12-29       Impact factor: 7.452

2.  Atorvastatin Promotes Cytotoxicity and Reduces Migration and Proliferation of Human A172 Glioma Cells.

Authors:  Karen A Oliveira; Tharine Dal-Cim; Flávia G Lopes; Fabiana K Ludka; Cláudia B Nedel; Carla I Tasca
Journal:  Mol Neurobiol       Date:  2017-02-08       Impact factor: 5.590

3.  Glutamate receptor GRIA3--target of CUX1 and mediator of tumor progression in pancreatic cancer.

Authors:  Stefanie Ripka; Jan Riedel; Albrecht Neesse; Heidi Griesmann; Malte Buchholz; Volker Ellenrieder; Franz Moeller; Peter Barth; Thomas M Gress; Patrick Michl
Journal:  Neoplasia       Date:  2010-08       Impact factor: 5.715

4.  Reverse phase protein arrays enable glioblastoma molecular subtyping.

Authors:  Gregor Hutter; Martin Sailer; Tej Deepak Azad; André O von Bueren; Peter Nollau; Stephan Frank; Cristobal Tostado; Durga Sarvepalli; Arkasubhra Ghosh; Marie-Françoise Ritz; Jean-Louis Boulay; Luigi Mariani
Journal:  J Neurooncol       Date:  2016-11-17       Impact factor: 4.130

5.  Knockdown of GluA2 induces apoptosis in non-small-cell lung cancer A549 cells through the p53 signaling pathway.

Authors:  Hong-Yan Zhang; Wei Yang; Ji-Bin Lu
Journal:  Oncol Lett       Date:  2017-05-24       Impact factor: 2.967

6.  Phase 2 trial of talampanel, a glutamate receptor inhibitor, for adults with recurrent malignant gliomas.

Authors:  Fabio M Iwamoto; Teri N Kreisl; Lyndon Kim; J Paul Duic; John A Butman; Paul S Albert; Howard A Fine
Journal:  Cancer       Date:  2010-04-01       Impact factor: 6.860

7.  Seizure response to perampanel in drug-resistant epilepsy with gliomas: early observations.

Authors:  Charles Vecht; Alberto Duran-Peña; Caroline Houillier; Thomas Durand; Laurent Capelle; Gilles Huberfeld
Journal:  J Neurooncol       Date:  2017-05-10       Impact factor: 4.130

Review 8.  Glutamate transporters in the biology of malignant gliomas.

Authors:  Stephanie M Robert; Harald Sontheimer
Journal:  Cell Mol Life Sci       Date:  2013-11-27       Impact factor: 9.261

9.  AMPA receptors promote perivascular glioma invasion via beta1 integrin-dependent adhesion to the extracellular matrix.

Authors:  Yuji Piao; Li Lu; John de Groot
Journal:  Neuro Oncol       Date:  2008-10-28       Impact factor: 12.300

10.  Therapeutic efficacy of 188Re-liposome in a C26 murine colon carcinoma solid tumor model.

Authors:  Ya-Jen Chang; Chin-Wei Hsu; Chih-Hsien Chang; Keng-Li Lan; Gann Ting; Te-Wei Lee
Journal:  Invest New Drugs       Date:  2012-12-09       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.